INM Stock Analysis: Buy, Sell, or Hold?
INM - InMed Pharmaceuticals Inc. Common Shares
$1.46
-0.01 (-0.68%)
▼
5d:
-10.98%
30d:
-6.41%
90d:
+104.34%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Sep 23, 2026
Get Alerted When INM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: INM is down 11.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: INM is down 11.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: INM is currently trading at $1.46, which is considered oversold relative to its 30-day fair value range of $1.52 to $1.68.
Technical Outlook: Technically, INM is in a strong uptrend. The price is currently testing key support at $1.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.00 (+1269.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INM is in a strong uptrend. The price is currently testing key support at $1.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.00 (+1269.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.52 -
$1.68
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1269.9% below Wall St target ($20.00)
- WARNING: Recommendation downgraded due to -11.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.52 -
$1.68
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.42
Resistance Level
$2.33
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Wall Street Target
$20.00
(+1269.9%)
Revenue Growth (YoY)
-26.2%
Profit Margin
-172.2%
Share & Embed Analysis
Last updated: August 04, 2026 2:30 AM ET
Data refreshes hourly during market hours. Next update: 3:30 AM
Data refreshes hourly during market hours. Next update: 3:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 52 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 45 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
